Plant Name: Hydrastis canadensis
Taxonomic Information:
Plant ID: NPO1074
Plant Latin Name: Hydrastis canadensis
Taxonomy Genus: Hydrastis
Taxonomy Family: Ranunculaceae
Plant External Links:
NCBI TaxonomyDB:
13569
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Canada; United States; Belarus; ChinaTraditional Medicine System:
TCMMedicinal Functions:
Antibacterial; Antiperiodic; Antiseptic; Antispasmodic; Astringent; Cholagogue; Diuretic; Laxative; Sedative; Stomachic; Tonic
Geographical Distribution:
Canada; United States; Belarus; China
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| DRD1; DRD2; | |
| BCHE; ACHE; | |
| HIF1A; | |
| SMN1;SMN2; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.252E-11 | 2.725E-07 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 9.469E-08 | 1.586E-04 | BCHE, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.212E-07 | 1.759E-04 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.076E-07 | 2.153E-04 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.076E-07 | 2.153E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 5.102E-07 | 4.250E-04 | ACHE, BCHE, DRD1, DRD2 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 1.019E-06 | 7.179E-04 | ACHE, BCHE |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 1.070E-06 | 7.281E-04 | ADRA2B, ADRA2C, DRD2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.659E-06 | 1.032E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 3.054E-06 | 1.415E-03 | CYP2D6, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 3.054E-06 | 1.415E-03 | ADRA2B, ADRA2C |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 4.043E-06 | 1.747E-03 | ADRA2C, CHRM1, DRD1, DRD2, HIF1A, HTR2B, HTT, SMN1, SMN2 |
| BP | GO:0065007; biological regulation | GO:0051282; regulation of sequestering of calcium ion | 5.004E-06 | 1.981E-03 | DRD1, DRD2, HTR2B, HTT |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.565E-06 | 2.164E-03 | CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 6.104E-06 | 2.215E-03 | ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 6.104E-06 | 2.215E-03 | ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.104E-06 | 2.215E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.209E-06 | 2.883E-03 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 1.017E-05 | 3.255E-03 | DRD1, DRD2 |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 1.594E-05 | 4.449E-03 | DRD1, DRD2, HIF1A |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.981E-05 | 5.260E-03 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0042165; neurotransmitter binding | 2.031E-05 | 5.328E-03 | ACHE, BCHE, HTR2B |
| CC | GO:0044456; synapse part | GO:0043679; axon terminus | 2.406E-05 | 5.954E-03 | ADRA2C, CHRM1, DRD2 |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 2.841E-05 | 6.653E-03 | DRD1, DRD2 |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 2.841E-05 | 6.653E-03 | ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 2.841E-05 | 6.653E-03 | ADRA2B, ADRA2C |
| BP | GO:0023052; signaling | GO:0007267; cell-cell signaling | 3.000E-05 | 6.875E-03 | ADRA2B, ADRA2C, CHRM1, DRD1, DRD2, TSHR |
| BP | Unclassified; | GO:0003056; regulation of vascular smooth muscle contraction | 3.651E-05 | 7.718E-03 | ADRA2B, CHRM1 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 4.471E-05 | 9.099E-03 | ADRA2B, ADRA2C, CHRM1, DRD1, DRD2, HTR2B, SIGMAR1, TSHR |
| BP | GO:0032501; multicellular organismal process | GO:0030432; peristalsis | 4.561E-05 | 9.111E-03 | DRD1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.561E-05 | 9.111E-03 | CYP1A2, CYP2C19 |
| BP | GO:0032501; multicellular organismal process | GO:0007416; synapse assembly | 4.971E-05 | 9.665E-03 | ACHE, DRD1, DRD2 |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 6.681E-05 | 1.173E-02 | SMN1, SMN2 |
| CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 7.890E-05 | 1.283E-02 | SMN1, SMN2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 6.023E-09 | 2.891E-07 | CHRM1, HTR2B, DRD1, ADRA2C, DRD2, ADRA2B, TSHR |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 6.028E-07 | 1.447E-05 | CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.073E-06 | 4.917E-05 | CYP1A2, CYP3A4, CYP2C19 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 4.067E-05 | 4.880E-04 | CHRM1, DRD1, DRD2, TSHR |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.086E-05 | 4.883E-04 | CYP2D6, CYP1A2, CYP3A4 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 8.889E-05 | 6.095E-04 | HTR2B, DRD1, DRD2 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 7.201E-05 | 5.761E-04 | CYP1A2, CYP3A4, CYP2C19 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.818E-04 | 1.091E-03 | CYP2D6, HTR2B, CYP2C19 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 7.301E-04 | 3.894E-03 | CHRM1, HTR2B, DRD1 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 1.086E-03 | 5.214E-03 | DRD1, DRD2 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.903E-03 | 7.611E-03 | CYP1A2, CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.519E-03 | 6.626E-03 | CYP1A2, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| NA: NA | Itching | NA | DRD2; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; DRD1; DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; DRD1; DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| NA: NA | Vomiting | NA | DRD2; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; DRD2; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| NA: NA | False perceptions | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; DRD1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; DRD2; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | DRD2; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
| NA: NA | Hyperaemia | NA | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
